Contact this trialFirst, we need to learn more about you.
Antibody-Drug Conjugate
T-DXd for HER2 Positive Breast Cancer
Recruiting2 awardsPhase 3
San Diego, California
This trial is testing a new cancer drug called Trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer that has not responded to other treatments. The drug targets cancer cells with a specific marker and delivers a powerful drug to kill them. The study includes patients with and without brain metastasis to see how well the drug works and how safe it is. Trastuzumab deruxtecan is a new type of treatment that has shown impressive results in patients who have already received many other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service